Healthcare

Hydreight Technologies Acquires 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase up to 40%, and Establishes Strategic Partnership

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Nov. 28,...

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the...

Thanksgiving Wishes to the DEA’s Anti Cannabis Holdouts – And Gently Suggests They Spend a Moment Thinking About Patients Waiting for Legal Medicine

MMJ Wishes DEA Officials a Happy Thanksgiving - While Reminding Them That Huntington's Chorea Doesn't Take Holidays. WASHINGTON, D.C. /...

Internet of Behaviors Market Surges to USD 14.3 Billion by 2033, Propelled by 26.5% CAGR – Verified Market Reports®

Internet of Behaviors (IoB) market projection signals robust CAGR driven by exponential data proliferation, AI-driven behavioral analytics and cross-channel orchestration....

AdvaHealth Solutions Unveils AdvaPACS, a Cloud-Native and AI-Forward Imaging Platform Built for Modern Radiology Workflows with No Upfront Costs and Flexible OpEx Pricing

A complete cloud imaging platform (PACS + VNA) designed for scalability, AI-enabled workflows, faster reporting, and operational efficiency, without infrastructure,...

Hydreight Reports 132% YoY Revenue Increase in Q3 2025 and Fourth Consecutive Quarter of Profitability, Highlighting Strong Multi-Vertical Performance

“The quarter reflects broad growth across all verticals, expanding VSDHOne adoption, and strategic investments aimed at supporting margin improvement and...

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies...

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real...

error: Content is protected !!